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THE STUDY 1.The participating Cancer Registries in EU and US cover only a non 
probabilistic sampling fraction of the population in the two 
continents. It is unclear whether the study took into account the 
different size and the different age and sex distributions of the 
population in the sample, compared with the age and sex 
distributions in Europe and in US population. If not, the results would 
be applicable only to those areas where the participating Registries 
are positioned.  
In tables 1,2, 3 it seems that no adjusted estimates by size, age, 
gender have been performed (no mention about in the legenda of 
the tables)  
Also the results survival analysis, which is statistically appropriate, 
could be biased if not weighted by population sizes.  
 
2.The 5 years survival follow up ended , at latest, in 2003. The cases 
were diagnosed between 1996 and 1998. The study reflects the 
clinical practice for treatment (and staging) of 15 -17 years ago.  
The authors should acknowledge this limitation, saying that the 
current situation could be different.  
 
3.Around 40% of US citizens ever had FOBT or sigmoidoscopy in 
US in 1997 as reported by a survey. Any effect on survival? 
(http://www.cdc.gov/mmwr/preview/mmwrhtml/00056494.htm) 
RESULTS & CONCLUSIONS I would prefer to not respond to the first 2 previuos questions, 
waiting further answers from the authors about the representiveness 
of the sample of colon cancer cases. 
 
REVIEWER María-Dolores Chirlaque. MD, Pblc Hlth specialist, MHSc. My 
institution is:  
1) Murcia Cancer Registry, Murcia Regional Health Authority, Spain  
2) CIBER Epidemiología y Salud Pública (CIBERESP), Spain  
 
I declare No conflict of interest. 
REVIEW RETURNED 07-May-2013 
 
REPORTING & ETHICS The authors should indicate whether conflict of interest exists.  
Also they should add some information about the ethical aspects of 
the study and the confidentiality of the information. 
GENERAL COMMENTS You have prepared an good paper on colorectal cancer survival. The 
complexity of variables influencing the outcome on colon and rectum 
cancer prognosis is a challenge for clinical and epidemiological 
research, and novel results are always welcome. Besides, the study 
has been well designed and analysed, involving a large amount of 
work and data.  
A limitation in high resolution studies on cancer prognosis is the 
difficult integration between clinical results and populations results. It 
is appreciated the effort realized in the present work just to integrate 
this two worlds.  
The main concern is about the clarification and description in 
methods sections of the main quality indicator of care use in the 
present study related to colon and rectum cancer process. The 
definition of standard care use in the present analysis to evaluate 
the adherence to guidelines is scarce and only in the last paragraph 
of the method is mentioned. The percentage of completeness of 
standard care indicators is an important issue to interpreter 
differences in prognosis. Besides, standard care indicator will need a 
reference.  
Abstract  
The objective of the study is not specified in the abstract.  
The background only mentions colorectal cancer survival but also 
adherence to standard care in patients suffering from colorectal 
cancer have also been evaluated.  
It is not clear whether the 12523 adults diagnosed with colorectal 
cancer during 1996-98 correspond to all incident cases or are a 
selection of cases. The authors should add that the cases included 
represent a sample.  
The survival estimates it supposed be at 5 years of first diagnosis 
(incidence date) and it should be detailed in M&M.  
In the conclusion you said „Elderly patients received surgery…. less 
often than younger patients…‟ and in results no data about surgery 
and age have been showed.  
Introduction / Material and methods / Discussion  
Second paragraph of the introduction: „in one of 31 countries‟, do 
you want to say: in each one of the 31 participating countries or 
countries included in the study?  
In methods, more information is required to understand the number 
of cases included and the method use to calculate the sample.  
The population based sample of patient diagnoses in Finland was 
representative of Finland, but, what happen with the other countries 
without national coverage? You should specify the percentage of 
cover population in countries without national coverage (in methods) 
and comment (in discussion) possible differences within the 
countries in adherence to standard care.  
Following the international rules for multiple primary cancers (ICD-O 
3rd Edition), colon and rectum site (C18 and C19-C20 respectively) 
are considered two different primary tumours. Thus, in the present 
study, what is the meaning that only primary malignant colorectal 
were included? If a patient had a colon cancer and afterwards a 
rectum cancer, the last one was excluded? Moreover, only if the first 
primary tumour corresponds to colon or rectum has been included in 
the present analysis? Otherwise, colon and rectum tumour 
diagnosed after other tumour site (breast, prostate, etc.) are 
excluded? This point should clarify in methods and take into account 
in the results and the discussion.  
A suggestion is that briefly explain the meaning of net cancer-
specific survival like cancer survival in the absence of other causes 
of death (the confounding effects of death from other causes are 
removed), if so.  
Resected patient for whom no pathology report was available were 
classified as stage unknown. Is this the same percentage that cases 
no verified microscopically? If not, you should include this 
information in results.  
A sub-analysis could be done with the age group of the screening 
programs of colorectal cancer that mainly are focused in the 50-69 
year age group. For instance, 15-49, 50-69 and 70+. This could be 
an exploratory or additional analysis. It will be useful to interpreter 
differences in results attributable to irregular development of 
screening programs across countries or continents, or to the varying 
nature (population or opportunistic) of the program.  
An important factor to take into account is the interpretations of 
results on prognosis of colon and rectal cancer in a wider context is 
the increasing presence of adenomatous polyp, villous adenoma or 
tubulovillous adenoma and their respective adenocarcinomas in situ 
suppose a better survival. All these cases are not included in the 
study and their prognosis is excellent. The higher premalignant 
lesions remove the better prognosis of colon and rectal cancer. 
Some comment could be addressed in the discussion about the 
effect of early diagnosis at population level in the general prognosis 
of colorectal cancer. This aspect can not be measure in the present 
study but should be commented.  
The draft should describe the correspondence between Dukes A, B, 
C D, the TNM and local, locally advanced, node-positive and 
metastatic disease in methods.  
On page 9, paragraph between lines 9-11, information on surgical 
procedures is not mentioned after in all the analysis, neither results 
nor discussion. That, is this a relevant information to include if no 
results are given?  
If the incidence date is the date to calculate the days/month/ or 
years of follow-up and the definition of incidence date is different in 
the Europe and the USA, should be specify in methods and 
commented in the discussion. This comment is relevant perhaps 
only in the interpretation of death within 30 days.  
A suggestion is to comment the incidence rate in US and in Europe, 
by sex and how it could this influence in survival.  
References  
In the reference 8 the authors are repeated.  
Figures and tables  
Table 1, column of colon: add a little explanation, like versus rectum.  
Table 2: the fourth last column add to Staged: known staged. The 
same in Table 2-web appendix, in the column of Staged.  
In one table (for example table 1) the authors could add the 
countries included in Northern, Western, Southern and Eastern 
European regions.  
In the Figure 5-web appendix change the scale of the graph Dukes 
A to 500 (number of excess death by 1000) just to compare with 
Dukes B and C.  
In table 3 the authors show the percentage of adjuvant 
chemotherapy and radiotherapy by Dukes stage, but how much is 
the optimal range of the percentage? This information is only 
mentioned in the discussion and this point is related to the 
description in method of quality indicator of care. 
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R1_C1.The participating Cancer Registries in EU and US cover only a non probabilistic sampling 
fraction of the population in the two continents. It is unclear whether the study took into account the 
different size and the different age and sex distributions of the population in the sample, compared 
with the age and sex distributions in Europe and in US population. If not, the results would be 
applicable only to those areas where the participating Registries are positioned.  
 
In tables 1,2, 3 it seems that no adjusted estimates by size, age, gender have been performed (no 
mention about in the legenda of the tables)  
 
Also the results survival analysis, which is statistically appropriate, could be biased if not weighted by 
population sizes.  
 
R1_A1. We completely understand the importance of the sampling of patients for studies of this kind. 
Doug Altman‟s text “Practical statistics for medical research” (Chapman and Hall, 1992, p6) notes: “In 
theory we can obtain a truly representative sample only by choosing patients at random but even then 
the sample would be specific to a time period and geographical area. In practice, samples are nearly 
always chosen systematically and the subjects‟ characteristics are described so that their 
representativeness can be judged.” We need to emphasise that we took truly random samples of 
patients from each cancer registry.  
 
The remainder of this comment appears to arise from a misunderstanding of the design of high-
resolution studies. Participating cancer registries are population-based, in that they register all 
persons diagnosed with a relevant malignancy in the defined territory that they cover. The patients 
included in high-resolution studies are large, randomly selected subsets of all persons diagnosed with 
a given cancer (here, colorectal), in a given calendar period (1996-98), in that territory. These 
samples are not intended to be “representative” of all cancer patients, either in Europe or the US. But 
they are representative of all colorectal cancer patients diagnosed during 1996-98 in the territory of 
each registry. And that is precisely the point. We are not attempting to establish international or inter-
continental league tables of cancer survival. We are attempting to obtain robust and genuinely 
representative estimates of the differences in survival between populations (whether those 
populations are regional or national) and of the impact on those population-based differences in 
cancer survival of covariables such as stage at diagnosis. For a more extended discussion of this 
point, see Coleman MP et al. EUROCARE-3 summary: cancer survival in Europe at the end of the 
20th century. Ann Oncol 2003; 14 (Suppl 5); 128-149.  
 
We only report the actual estimates of survival to confirm that those international differences reported 
in previous studies are reflected in our data. There is thus no reason to weight the survival estimates 
by the age and sex distributions of persons in Europe and the US (and if any such weighting were 
required, it would be by the age-sex distribution of cancer patients, and not of the general population: 
the same point applies to age standardisation of cancer survival estimates).  
 
When only a single participating cancer registry is available for a wider region, such as Finland in the 
Nordic area of Europe, we need to be careful not to overemphasise the survival estimates for that 
region, but this point was clearly mentioned in the “strength and limitations” section of the bullet points 
we were asked to prepare to summarise the study. To make clear which geographical areas we are 
actually comparing, we have added a footnote to all tables and graphs.  
 
Table 1, 2 and 3 are simple descriptive distributions of the numbers of cases in various categories: 
such tables are not usually adjusted, and it is not clear what standard weights would be appropriate!  
 
R1_C2. The 5 years survival follow up ended, at latest, in 2003. The cases were diagnosed between 
1996 and 1998. The study reflects the clinical practice for treatment (and staging) of 15 -17 years ago.  
The authors should acknowledge this limitation, saying that the current situation could be different.  
 
R1_A2. We agree. We included exactly this point under the heading “strengths and limitations” among 
the same bullet points:  
 
• Most diagnostic and therapeutic approaches used in the late 1990s remain in widespread use; 
mesorectal excision for rectal cancer is more recent. It remains relevant to understand the extent to 
which investigation and treatment are responsible for the persistent international differences in 
colorectal cancer survival.  
 
R1_C3. Around 40% of US citizens ever had FOBT or sigmoidoscopy in US in 1997 as reported by a 
survey. Any effect on survival?  
(http://www.cdc.gov/mmwr/preview/mmwrhtml/00056494.htm)  
 
R1_A3. Thank you for this point and for the helpful reference.  
 
European guidelines on population-based screening for colorectal malignancy were published in 
2003, and none of the countries involved in this study had introduced it before 2006.  
 
We agree that opportunistic testing with faecal occult blood or sigmoidoscopy was more common in 
the US than in Europe in the late 1990s. We do not have information on whether or not the patients in 
this study had undergone FOBT or endoscopic examination at any time before their diagnosis, 
because these facts are not routinely recorded at cancer registration, and we cannot rely on partial 
information that may be available in the clinical record. Given that a higher proportion of patients in 
the US than in Europe had undergone a diagnostic procedure that could have resulted in removal of a 
premalignant polyp or an in situ neoplasm, it is worth considering the impact of this potential bias on 
the difference in survival between the US and Europe. It would be expected to reduce incidence, shift 
the spectrum of malignancy to the right, and reduce survival. In fact, incidence in the US is higher, the 
stage distribution less advanced, and survival higher than in Europe. In short, to the extent that the 
bias suggested by the referee exists, it would be expected to have reduced the difference in survival 
between the US and Europe.  
 
We have added a comment to this effect to the discussion.  
 
R1_C4. I would prefer to not respond to the first 2 previuos questions (Do the results answer the 
research question? Are they credible?), waiting further answers from the authors about the 
representiveness of the sample of colon cancer cases.  
 
R1_A4. We have addressed this point higher up (R1_A1).  
 
   
Reviewer: María-Dolores Chirlaque. MD, Pblc Hlth specialist, MHSc. My institution is:  
1) Murcia Cancer Registry, Murcia Regional Health Authority, Spain  
2) CIBER Epidemiología y Salud Pública (CIBERESP), Spain  
 
I declare No conflict of interest.  
 
The authors should indicate whether conflict of interest exists.  
 
Also they should add some information about the ethical aspects of the study and the confidentiality of 
the information.  
 
As requested by BMJ Open, we reported this information in the website ad hoc space during the 
submission. In the light of this comment, we have now added this information to the article.  
 
Dear colleagues  
 
You have prepared an good paper on colorectal cancer survival. The complexity of variables 
influencing the outcome on colon and rectum cancer prognosis is a challenge for clinical and 
epidemiological research, and novel results are always welcome. Besides, the study has been well 
designed and analysed, involving a large amount of work and data.  
 
A limitation in high resolution studies on cancer prognosis is the difficult integration between clinical 
results and populations results. It is appreciated the effort realized in the present work just to integrate 
this two worlds.  
 
The main concern is about the clarification and description in methods sections of the main quality 
indicator of care use in the present study related to colon and rectum cancer process. The definition 
of standard care use in the present analysis to evaluate the adherence to guidelines is scarce and 
only in the last paragraph of the method is mentioned. The percentage of completeness of standard 
care indicators is an important issue to interpreter differences in prognosis. Besides, standard care 
indicator will need a reference.  
 
 
We appreciate these constructive comments.  
 
We have added references to the indicator of standard care.  
 
Abstract  
R2_C1 The objective of the study is not specified in the abstract.  
The background only mentions colorectal cancer survival but also adherence to standard care in 
patients suffering from colorectal cancer have also been evaluated.  
It is not clear whether the 12523 adults diagnosed with colorectal cancer during 1996-98 correspond 
to all incident cases or are a selection of cases. The authors should add that the cases included 
represent a sample.  
 
R2_A1: Thank you for your thorough reading of the abstract, which is unfortunately very tightly 
constrained on word length. We have not explicitly stated the objective, as requested, but we feel the 
objective is nevertheless clear from the second paragraph of materials and methods in the abstract. 
Evaluation of adherence to standard care is also covered in this paragraph.  
 
R2_C2: The survival estimates it supposed be at 5 years of first diagnosis (incidence date) and it 
should be detailed in M&M.  
R2_A2: We assume this comment also refers to the abstract. The same constraints on length applied. 
In the Material and Method paragraph we wrote: “Net survival and excess risk of death were 
estimated with flexible parametric models”, but in the Results section we wrote: “Age-standardised 
five-year net survival was...”; we therefore believe it is clear that we estimated 5-year net survival. It is 
also explicit in the Statistical analysis section of the body of the article: “Net survival up to five years 
after diagnosis was estimated by geographical area (UN region of Europe, country, registry or US 
state), age and stage, using flexible parametric excess hazard models.”  
 
R2_C3: In the conclusion you said „Elderly patients received surgery…. less often than younger 
patients…‟ and in results no data about surgery and age have been showed.  
 
R2_A3: We are puzzled by this point. We have written: “Patients aged less than 75 years were only 
half as likely to be resected with curative intent as those aged 15-64 years (OR 0.48, 95% confidence 
interval [CI] 0.43-0.53), after adjustment for region and tumour site.” (Table 4)  
 
Introduction / Material and methods / Discussion  
R2_C4: Second paragraph of the introduction: „in one of 31 countries‟, do you want to say: in each 
one of the 31 participating countries or countries included in the study?  
 
R2_A4: Thank you for the clarification: “... in 31 countries”!  
 
R2_C5: In methods, more information is required to understand the number of cases included and the 
method use to calculate the sample.  
 
R2_A5: This point is reported in the Material and Methods section: “Most registries provided a random 
sample of at least 500 patients diagnosed during 1996-98 (1997 in the US).”  
We asked the registries for a random (and thus representative) sample of about 500 cases as 
reported below, but we did not instruct the registries to use a specific method to obtain their random 
samples. A few registries simply sent all colorectal cancer patients registered in 1, 2 or 3 years during 
the period 1996-98.  
 
R2_C6: The population based sample of patient diagnoses in Finland was representative of Finland, 
but, what happen with the other countries without national coverage? You should specify the 
percentage of cover population in countries without national coverage (in methods) and comment (in 
discussion) possible differences within the countries in adherence to standard care.  
 
R2_A6: It is important not to see the description and comparisons of patterns of care within and 
between countries (or regions of countries) as an international league table. The percentage of the 
(national) population covered by a given cancer registry does not influence adherence to standard 
care in that region. If a registry is population-based, its data provide, by definition, a picture of the 
effectiveness of the health system in the territory covered by the registry, regardless of its size. The 
design of studies such as this is intended to provide robustly comparable estimates of the relative 
importance of covariables in explaining the survival differences that are observed in each region or 
country. If the health system is not working properly in a given area, this should be considered a 
problem for the whole country.  
 
R2_C7: Following the international rules for multiple primary cancers (ICD-O 3rd Edition), colon and 
rectum site (C18 and C19-C20 respectively) are considered two different primary tumours. Thus, in 
the present study, what is the meaning that only primary malignant colorectal were included? If a 
patient had a colon cancer and afterwards a rectum cancer, the last one was excluded? Moreover, 
only if the first primary tumour corresponds to colon or rectum has been included in the present 
analysis? Otherwise, colon and rectum tumour diagnosed after other tumour site (breast, prostate, 
etc.) are excluded? This point should clarify in methods and take into account in the results and the 
discussion.  
 
R2_A7: We included cases with a cancer of colon or rectum (ICD-9 153-154; herein: colorectum) 
diagnosed during 1996-98. Only invasive malignant (behaviour code 3) and in situ (2) tumours were 
collected. Uncertain and borderline (1) tumours were excluded. Both histologically verified and not 
verified cases were included.  
 
A colorectal tumour diagnosed after another primary cancer was included only if the first tumour 
occurred in a different organ. Second colorectal cancers therefore were not notified as independent 
cases.  
 
Persons with two or more synchronous colorectal cancers were included and treated as a single case; 
both (all) localisations were recorded, as well as the most advanced stage.  
 
R2_C8: A suggestion is that briefly explain the meaning of net cancer-specific survival like cancer 
survival in the absence of other causes of death (the confounding effects of death from other causes 
are removed), if so.  
 
R2_A8: We explained the meaning of net survival with phrasing similar to that suggested by the 
reviewer in the Statistical analysis paragraph (page 9): “Net survival is the survival of cancer patients 
in the hypothetical situation where the cancer may be assumed to be the only possible cause of 
death; it may be interpreted as cancer survival after controlling for competing causes of death.”  
 
R2_C9: Resected patient for whom no pathology report was available were classified as stage 
unknown. Is this the same percentage that cases no verified microscopically? If not, you should 
include this information in results.  
 
R2_A9: Thank you for pointing out this weakness in the drafting. For the purposes of describing a 
broad category of patients whose disease was advanced at diagnosis, we combined patients whose 
pathology reports identified metastatic disease with patients who were not resected and for whom no 
pathology was available. The second of these two groups is widely accepted as likely to have had 
advanced disease, the absence of invasive diagnostic procedures being most probably attributable to 
a decision not to attempt surgery of curative intent (e.g. a bypass procedure in the biliary or digestive 
tract, or insertion of a stoma), because of the extent of disease, usually peritoneal carcinomatosis. 
This is the category described as “advanced stage” in table 2, with the definition in footnote 1.  
 
This broad category was not used in stage-specific survival analyses, however. For those analyses, 
we use the classical Dukes‟ stage, where available.  
 
We have made this more clear in the text.  
 
R2_C10: A sub-analysis could be done with the age group of the screening programs of colorectal 
cancer that mainly are focused in the 50-69 year age group. For instance, 15-49, 50-69 and 70+. This 
could be an exploratory or additional analysis. It will be useful to interpreter differences in results 
attributable to irregular development of screening programs across countries or continents, or to the 
varying nature (population or opportunistic) of the program.  
 
R2_A10: We adopted these age groups to be the same as those in previous studies of the patterns of 
care for colorectal malignancy (Gatta et al. Acta Oncol. 2010; 49: 776-783). The Council of the 
European Union indicated the utility of population-based screening for colorectal cancer in 2003, but 
the European guidelines were not written until a couple of years later. Population-based screening 
was only introduced in 2006, and is still not very widespread. We did not have information on whether 
the patients in this study had undergone faecal occult blood testing or endoscopy prior to diagnosis.  
 
R2_C11: An important factor to take into account is the interpretations of results on prognosis of colon 
and rectal cancer in a wider context is the increasing presence of adenomatous polyp, villous 
adenoma or tubulovillous adenoma and their respective adenocarcinomas in situ suppose a better 
survival. All these cases are not included in the study and their prognosis is excellent. The higher 
premalignant lesions remove the better prognosis of colon and rectal cancer. Some comment could 
be addressed in the discussion about the effect of early diagnosis at population level in the general 
prognosis of colorectal cancer. This aspect can not be measure in the present study but should be 
commented.  
 
R2_A11: We agree that exclusion from the analyses of tumours with better prognosis will lead to 
higher estimates of survival. (Referee 1 comment 3 addresses a similar point). In turn, the frequency 
with which premalignant polyps, adenomas and in situ malignancies are removed (reducing the 
recorded incidence of invasive disease and shifting the biological spectrum of malignancy to the 
right), can influence population-based survival estimates. Again, although it is a fairly safe assumption 
that this frequency is higher in the US than in the range of European countries included in the study, 
we had no specific information on whether the patients in this study had undergone endoscopic 
removal of any premalignant lesions. In situ tumours were not included in the analyses because data 
for these tumours were only supplied by US registries (396, 3.1%).  
 
We have added a suitable comment to the discussion.  
 
R2_C12: The draft should describe the correspondence between Dukes A, B, C D, the TNM and 
local, locally advanced, node-positive and metastatic disease in methods.  
 
R2_A12: We have tried to keep this complex paper as simple as possible! Dukes‟ stage can be 
constructed from complete TNM data, but we have used Dukes‟ stage in the analyses for the reasons 
mentioned in the text, and have preferred to add a note to all tables including information about stage.  
 
R2_C13: On page 9, paragraph between lines 9-11, information on surgical procedures is not 
mentioned after in all the analysis, neither results nor discussion. That, is this a relevant information to 
include if no results are given?  
 
R2_A13: We agree, and we removed this sentence. Much more detailed information was collected 
about surgical procedures, and this was initially used to categorise the site and extent of surgery, but 
in the end, this was not used to analyse outcomes because it was insufficiently complete.  
 
R2_C14: If the incidence date is the date to calculate the days/month/ or years of follow-up and the 
definition of incidence date is different in the Europe and the USA, should be specify in methods and 
commented in the discussion. This comment is relevant perhaps only in the interpretation of death 
within 30 days.  
 
R2_A14: There are international rules to define the date of incidence. These rules are followed by all 
registries contributing data to international studies such as Cancer Incidence in Five Continents. If a 
registry considered a given date as the date of incidence we had no reason to assume it was not 
coded according to the international rules. More importantly, differences in 30 day post-operative 
mortality were small, and we did not see fit to comment on them in the discussion.  
 
R2_C15: A suggestion is to comment the incidence rate in US and in Europe, by sex and how it could 
this influence in survival.  
 
R2_A15: We appreciate that incidence, survival and mortality are closely related, but our main 
concern was to explore the predictors of differences in survival, rather than to describe the overall 
patterns of survival, and in particular their trends over time; if we had been carrying out such an 
exercise, comparisons of incidence would certainly have been helpful. We have preferred not to 
accept this suggestion, partly also for reasons of space.  
 
   
References  
R2_C16: In the reference 8 the authors are repeated.  
 
R2_A16: Thank you. We have corrected the reference.  
 
Figures and tables  
R2_C17: Table 1, column of colon: add a little explanation, like versus rectum.  
 
R2_A17: In table 1 colon indicates the No. and % of patients with colon cancer out of all the colorectal 
cancer patients.  
 
R2_C18: Table 2: the fourth last column add to Staged: known staged. The same in Table 2-web 
appendix, in the column of Staged.  
 
R2_A18: We prefer to leave this one! “Staged” does make clear that stage was known.  
 
R2_C19: In one table (for example table 1) the authors could add the countries included in Northern, 
Western, Southern and Eastern European regions.  
 
R2_A19: Thank you. We have added a footnote to all tables and graphs.  
 
R2_C20: In the Figure 5-web appendix change the scale of the graph Dukes A to 500 (number of 
excess death by 1000) just to compare with Dukes B and C.  
 
R2_A20: We agree in principle that it is preferable to use the same scale for the y-axis when there are 
several similar graphics, in order to facilitate visual comparison. However, adopting this suggestion 
would completely suppress the visual difference in the excess hazard by region for Dukes‟ A 
malignancy. We did try it!  
 
R2_C21: In table 3 the authors show the percentage of adjuvant chemotherapy and radiotherapy by 
Dukes stage, but how much is the optimal range of the percentage? This information is only 
mentioned in the discussion and this point is related to the description in method of quality indicator of 
care.  
 
R2_A21: No optimal percentage had been proposed in the late 1990s. During the early and mid-
2000s, chemotherapy was considered to be indicated for all patients with a Dukes C‟ tumour, but 
some co-morbidities or other contraindication to chemotherapeutic agents also applied. In practice 
about 90% of patients under 75 are treated with chemotherapy in France and about 60% in older 
patients. (Bouvier et al. Dig Liver Dis 2013; Quipourt et al. J Am Geriatr Soc 2011; Phelip et al. 
Gastroenterol Clin Biol 2010)  
 
VERSION 2 – REVIEW 
REVIEWER  
Nereo Segnan MD MSc Epi  
 
Head, Department of Cancer Screening and Unit of Cancer 
Epidemiology  
Centre for Epidemiology and Prevention in Oncology, CPO 
Piedmont  
Hospital “City of Health and Science”, Turin, Italy  
IARC Senior Visiting Scientist 
REVIEW RETURNED 12-Jun-2013 
 
THE STUDY The title of the study "Colorectal cancer survival in the US and 
Europe: a CONCORD high-resolution study", the results section of 
the abstract , the article focus and the key messages are suggesting 
that the authors attempt to compare the survival in US and Europe . 
Only 7 of US cancer registries are included , and in Europe countries 
like Germany or UK are excluded. The title, abstract and “focus” 
should be modified according to. Perhaps the presentation of the 
limits of the study and of its generalisability was not complete in the 
manuscript.I would suggest to report in the text the following 
sentence in order to avoid in the reader any risk of over-
interpretation or misunderstanding of high resolution studies. The 
sentence is part of the authors reply R1_A1 to the the R1_C1 
comment:” Participating cancer registries are population-based, in 
that they register all persons diagnosed with a relevant malignancy 
in the defined territory that they cover. The patients included in high-
resolution studies are large, randomly selected subsets of all 
persons diagnosed with a given cancer (here, colorectal), in a given 
calendar period (1996-98), in that territory. These samples are not 
intended to be “representative” of all cancer patients, either in 
Europe or the US. But they are representative of all colorectal 
cancer patients diagnosed during 1996-98 in the territory of each 
registry. And that is precisely the point. We are not attempting to 
establish international or inter-continental league tables of cancer 
survival.  
 
 
In the same reply R1_A1 the corresponding author wrote: ”Table 1, 
2 and 3 are simple descriptive distributions of the numbers of cases 
in various categories: such tables are not usually adjusted, and it is 
not clear what standard weights would be appropriate!"  
A rectangular sample by age and gender (or stratified proportions by 
age and gender) would permit to compare the distributions across 
the registries of cancer site, stage, chemotherapy ........  
The tables 1-3 which document the sampling results , show for 
instance a proportion of colorectal cancer in males in European 
registries between 45% and 60%e and of colon cancer between 
49% and 68%. The proportions by gender or site of colorectal 
cancer of course reflect the age distribution of patients. Perhaps an 
effort to prevent any not appropriate interpretation by the not 
thoughtful reader could be considered by presenting the data as 
suggested. 
RESULTS & CONCLUSIONS The answers to unanswered questions in the "Results and 
conclusion" section depends on presenting the results according to 
their content. 
 
 
VERSION 2 – AUTHOR RESPONSE 
Claudia Allemani  
 
 
R1_C1: The title of the study "Colorectal cancer survival in the US and Europe: a CONCORD high-
resolution study", the results section of the abstract, the article focus and the key messages are 
suggesting that the authors attempt to compare the survival in US and Europe . Only 7 of US cancer 
registries are included, and in Europe countries like Germany or UK are excluded. The title, abstract 
and “focus” should be modified according to.  
 
R1_A1: We understand the concern of the referee, which relate to the title, the abstract (results), the 
article focus and the key messages.  
 
We would argue that the title is precisely accurate. We are indeed comparing survival in the US and 
Europe – but the comparison is clearly not between the whole of the US and the whole of Europe. We 
do not accept that this could possibly be considered misleading. No study has ever included data from 
all of the US cancer registries. Many of those registries only started operation in the late 1990s. 
Despite that, the data from the SEER programme are widely reported as if they were, in fact, the only 
US data (SEER covered 10% of the US population up to 1992 and from 14% up to the current 26% 
only much more recently), and as if they were indeed representative of the US, which they are 
not.[1,2] Nor has any study ever included data from all European countries, quite a few of which either 
have no cancer registry or a registry which only began operation within the last 10 years.  
 
The abstract for this paper emphasises that “21 population-based registries in 7 US states and 9 
European countries” participated in the study.  
 
The key messages state that “Stage at diagnosis varied more widely between [participating] 
European countries than between [participating] US states”: we have modified this to meet the 
referee‟s concern by the inclusion of the word “participating”.  
 
1. Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results 
(SEER) Program cancer data of the United States? Cancer Causes Control 2004; 15: 1027-34  
2. Coleman MP, Quaresma M, Berrino F, Lutz J-M, De Angelis R, Capocaccia R, Baili P, Rachet B, 
Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, Azevedo e 
Silva G, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL, CONCORD Working Group. 
Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 
2008; 9: 730-56  
 
R1_C2: Perhaps the presentation of the limits of the study and of its generalisability was not complete 
in the manuscript. I would suggest to report in the text the following sentence in order to avoid in the 
reader any risk of over-interpretation or misunderstanding of high resolution studies. The sentence is 
part of the authors reply R1_A1 to the the R1_C1 comment:” Participating cancer registries are 
population-based, in that they register all persons diagnosed with a relevant malignancy in the defined 
territory that they cover. The patients included in high-resolution studies are large, randomly selected 
subsets of all persons diagnosed with a given cancer (here, colorectal), in a given calendar period 
(1996-98), in that territory. These samples are not intended to be “representative” of all cancer 
patients, either in Europe or the US. But they are representative of all colorectal cancer patients 
diagnosed during 1996-98 in the territory of each registry. And that is precisely the point. We are not 
attempting to establish international or inter-continental league tables of cancer survival.  
 
R1_A2: Thank you. We have added this material to the discussion.  
 
R1_C3: In the same reply R1_A1 the corresponding author wrote: "Table 1, 2 and 3 are simple 
descriptive distributions of the numbers of cases in various categories: such tables are not usually 
adjusted, and it is not clear what standard weights would be appropriate!"  
A rectangular sample by age and gender (or stratified proportions by age and gender) would permit to 
compare the distributions across the registries of cancer site, stage, chemotherapy ........ The tables 
1-3 which document the sampling results , show for instance a proportion of colorectal cancer in 
males in European registries between 45% and 60%e and of colon cancer between 49% and 68%. 
The proportions by gender or site of colorectal cancer of course reflect the age distribution of patients. 
Perhaps an effort to prevent any not appropriate interpretation by the not thoughtful reader could be 
considered by presenting the data as suggested.  
 
R1_A3: The referee is correct that age-incidence differs between males and females, primarily for 
rectal rather than colon cancer. This information is readily available from standard publications, and it 
does not seem appropriate to reproduce these distributions here, when the purpose is to examine 
broad international differences in treatment among large random samples of the cancer patient 
population, taking due account of age and sex.  
 
To break down Tables 1-3 by sex and by three or four categories of age would make these already 
substantial tables 6 to 8 times larger than they currently are, and we do not believe this is likely to be 
publishable, or greatly to enhance the interpretability of the information by readers – especially if the 
expansion of the tables also included data for individual registries rather than broad geographic 
regions. It is surely more important that the key analyses are adjusted for age and sex where 
necessary. The models of treatment by sub-site and stage (Table 4) all include age: the age-specific 
differences in treatment, particularly in the elderly, are fully discussed in the article. We would also 
point out that the odds of resection for curative intent (Table 4) are adjusted for sub-site, but there is 
no evidence that sex is a confounder. The model for radiotherapy in Dukes‟ stage A-C rectal cancer 
includes sex: there is no evidence of a difference between the sexes in the odds of receiving 
radiotherapy (95% CI 0.77-1.10); it seems unlikely that a thoughtful reader would misinterpret these 
data. 
